When you arrive at the location, you'll witness dozens of soldiers in the leaf glade battling Igan warriors ... his reasoning behind the plan and stress the fact that the aim is peace, and ...

The trial assessed the safety and efficacy of the therapy against placebo in patients with IgAN. Subjects treated with the therapy in conjunction with a RAS inhibitor experienced a reduction of 36 ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

We remain dedicated to working with our partners, regulators, and healthcare providers to expand access and improve outcomes for those affected by IgAN.” “The decision by the European ...

IgAN is a common, chronic autoimmune kidney disease that primarily affects young adults. In patients with the disease, a protein called immunoglobulin A (IgA) becomes trapped in the filters of the ...